Atglistatin
目录号 : GC15770
An inhibitor of adipose triglyceride lipase
Cas No.:1469924-27-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Atglistatin is a potent and selective inhibitor of ATGL with IC50 value of 0.7 μM [1].
Adipose triglyceride lipase (ATGL) is a rate-limiting enzyme in the mobilization of fatty acids from cellular triglyceride stores. Deregulated fatty acid metabolism may lead to metabolic disorders and dyslipidemic [1].
Atglistatin is a potent and selective ATGL inhibitor. In lysates from E. coli overexpressing ATGL, atglistatin inhibited ATGL activity with IC50 value of 0.7 μM. Atglistatin at concentrations up to 50 μM had no cytotoxicity. Also, atglistatin inhibited ATGL with Ki value of 355 nM in a competitive way. In white adipose tissue (WAT) lysates of wild-type mice, atglistatin inhibited triacylglycerol (TG) hydrolase activity by 78%. The combination of Atglistatin and the HSL inhibitor Hi 76-007917 inhibited TG hydrolase activity by 95%. In WAT cultures of wild-type mice, atglistatin reduced FA and glycerol release up to 72% and 62% respectively in the presence of forskolin [1].
In fasted wild-type C57Bl/6J mice, atglistatin inhibited lipolysis in a dose- and time-dependent way. Atglistatin reduced plasma TG levels by 43% and decreased glycerol and FA levels up to 62% and 50% respectively in a dose dependent way [1].
Reference:
[1]. Mayer N, Schweiger M, Romauch M, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol, 2013, 9(12): 785-787.
| Kinase experiment [1]: | |
|
Determination of lipase activity |
For determination of lipase activity, lysates are incubated with a substrate containing radiolabeled [9,10-3H(N)]-triolein. Subsequently, FA are extracted and quantitated by liquid scintilation counting. Data are presented as mean±S.D. of triplicate determinations and representative for at least three independent experiments. |
| Cell experiment [1]: | |
|
Cell lines |
3T3-L1 fibroblasts, AML-12 mouse hepatocytes |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.1, 1, 10, or 50 μM for 1-3 h |
|
Applications |
Atglistatin showed highest adipose triglyceride lipase (ATGL) inhibition potential with IC50 value of 0.7 μM. Atglistatin was highly effective in inhibiting lipolysis in 3T3-L1 adipocytes and white adipose tissue (WAT) organ cultures of wild-type mice by targeting ATGL. |
| Animal experiment [1]: | |
|
Animal models |
Mice (C57Bl/6J) model |
|
Dosage form |
200 μmol/kg; oral gavage or intraperitoneal administration, for 8 h; |
|
Applications |
Atglistatin showed the potential of inhibiting lipolysis in fasted wild-type C57Bl/6J mice. Atglistatin also caused a strong reduction in plasma triacylglycerol (TG) levels (-43%). |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: 1.Mayer, N., Schweiger, M., Romauch, M., Grabner, G. F., Eichmann, T. O., Fuchs, E., Ivkovic, J., Heier, C., Mrak, I., Lass, A., Hofler, G., Fledelius, C., Zechner, R., Zimmermann, R. and Breinbauer, R. (2013) Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol. 9, 785-787 |
|
| Cas No. | 1469924-27-3 | SDF | |
| 化学名 | 3-[3-[4-(dimethylamino)phenyl]phenyl]-1,1-dimethylurea | ||
| Canonical SMILES | CN(C)C1=CC=C(C=C1)C2=CC(=CC=C2)NC(=O)N(C)C | ||
| 分子式 | C17H21N3O | 分子量 | 283.37 |
| 溶解度 | ≥ 14.15mg/mL in DMSO | 储存条件 | Store at -20° C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.529 mL | 17.6448 mL | 35.2896 mL |
| 5 mM | 0.7058 mL | 3.529 mL | 7.0579 mL |
| 10 mM | 0.3529 mL | 1.7645 mL | 3.529 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet